Smita Asare

3.5k total citations
22 papers, 300 citations indexed

About

Smita Asare is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Smita Asare has authored 22 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Cancer Research and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Smita Asare's work include Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Smita Asare is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Cancer Genomics and Diagnostics (6 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Smita Asare collaborates with scholars based in United States, Australia and United Kingdom. Smita Asare's co-authors include Christina Yau, Douglas Yee, A. Jo Chien, Rita Nanda, Laura Esserman, Minetta C. Liu, Angela DeMichele, Andres Forero‐Torres, Erin D. Ellis and Anne M. Wallace and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Smita Asare

21 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Smita Asare United States	7	183	97	75	67	62	22	300
Nikoletta Sidiropoulos United States	8	163 0.9×	135 1.4×	34 0.5×	50 0.7×	114 1.8×	21	336
Benjamin Bonhomme France	8	131 0.7×	44 0.5×	35 0.5×	43 0.6×	81 1.3×	15	261
Jeroen Depreeuw Belgium	9	116 0.6×	151 1.6×	23 0.3×	29 0.4×	85 1.4×	13	491
Nicolai Aagaard Schultz Denmark	9	147 0.8×	149 1.5×	22 0.3×	81 1.2×	37 0.6×	21	322
Cor H. van der Leest Netherlands	7	206 1.1×	26 0.3×	93 1.2×	18 0.3×	110 1.8×	16	289
Andreas Kümmel Germany	6	214 1.2×	28 0.3×	96 1.3×	93 1.4×	122 2.0×	8	342
Geer Zhang China	6	165 0.9×	58 0.6×	133 1.8×	35 0.5×	83 1.3×	12	360
Burçin Baran Türkiye	4	254 1.4×	87 0.9×	15 0.2×	91 1.4×	86 1.4×	7	358
Graciela Cruz‐Rico Mexico	8	159 0.9×	85 0.9×	56 0.7×	29 0.4×	135 2.2×	26	314
Nicanor I. Barrena Medel United States	9	84 0.5×	71 0.7×	22 0.3×	82 1.2×	35 0.6×	9	650

Countries citing papers authored by Smita Asare

Since Specialization

Citations

This map shows the geographic impact of Smita Asare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Smita Asare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Smita Asare more than expected).

Fields of papers citing papers by Smita Asare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Smita Asare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Smita Asare. The network helps show where Smita Asare may publish in the future.

Co-authorship network of co-authors of Smita Asare

This figure shows the co-authorship network connecting the top 25 collaborators of Smita Asare. A scholar is included among the top collaborators of Smita Asare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Smita Asare. Smita Asare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Katharine, Amrita Basu, Christina Yau, et al.. (2023). Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Frontiers in Oncology. 13. 1192208–1192208. 2 indexed citations

Basu, Amrita, Michelle Melisko, Ruixiao Lu, et al.. (2023). Abstract GS5-04: Identification of symptoms that are associated with irAEs in the I-SPY clinical trial. Cancer Research. 83(5_Supplement). GS5–4. 1 indexed citations

Wolf, Denise M., Christina Yau, Michael J. Campbell, et al.. (2022). Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL. Cancer Research. 82(4_Supplement). P5–13. 2 indexed citations

Chien, A. Jo, Kevin Kalinsky, Rita A. Mukhtar, et al.. (2022). Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer. Cancer Research. 82(4_Supplement). OT1–10. 2 indexed citations

Soliman, Hatem, Denise M. Wolf, Christina Yau, et al.. (2022). Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies. Cancer Research. 82(4_Supplement). PD10–7. 1 indexed citations

Wolf, Denise M., Christina Yau, Lamorna Brown Swigart, et al.. (2021). Abstract PD14-02: Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer. Cancer Research. 81(4_Supplement). PD14–2. 1 indexed citations

Gibbs, David L., Adam L. Asare, Smita Asare, et al.. (2021). PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial. JAMIA Open. 4(2). ooab038–ooab038. 2 indexed citations

Sayaman, Rosalyn W., Denise M. Wolf, Christina Yau, et al.. (2020). Abstract P1-21-08: Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial. Cancer Research. 80(4_Supplement). P1–21. 1 indexed citations

Wolf, Denise M., Christina Yau, Julia Wulfkuhle, et al.. (2020). Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. npj Breast Cancer. 6(1). 48–48. 25 indexed citations

10.

Wolf, Denise M., Christina Yau, Julia Wulfkuhle, et al.. (2020). Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial. Cancer Research. 80(4_Supplement). P4–10.

11.

Wolf, Denise M., Christina Yau, Julia Wulfkuhle, et al.. (2019). Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial. Cancer Research. 79(13_Supplement). 2679–2679. 3 indexed citations

12.

Yau, Christina, Michael J. Campbell, Peter Savas, et al.. (2019). Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies. Cancer Research. 79(4_Supplement). P3–10. 7 indexed citations

13.

Campbell, Michael J., Christina Yau, Scott Vandenberg, et al.. (2019). Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL. Cancer Research. 79(13_Supplement). CT003–CT003. 10 indexed citations

14.

Yau, Christina, Denise M. Wolf, Lamorna Brown Swigart, et al.. (2018). Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer. Cancer Research. 78(4_Supplement). PD6–14. 6 indexed citations

15.

Campbell, Matthew T., Christina Yau, Alexander D. Borowsky, et al.. (2018). Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial. Cancer Research. 78(4_Supplement). PD6–8. 3 indexed citations

16.

Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations

17.

Shaked, Abraham, Bao‐Li Chang, Michael R. Barnes, et al.. (2016). An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection. Hepatology. 65(1). 269–280. 47 indexed citations

18.

Shaked, Abraham, Toumy Guettouche, Smita Asare, et al.. (2014). Potential Application of Serum miRNA Signature for Minimization of Immunosuppression and Diagnosis of Rejection Following Liver Transplantation.. Transplantation. 98. 230–230. 1 indexed citations

19.

Nelson, Elizabeth, et al.. (2013). Ancillary study management systems: a review of needs. BMC Medical Informatics and Decision Making. 13(1). 5–5. 4 indexed citations

20.

Chase, H. Peter, Lisa Rafkin‐Mervis, Heidi Krause‐Steinrauf, et al.. (2009). Nutritional Intervention to Prevent (NIP) Type 1 Diabetes A Pilot Trial. ICAN Infant Child & Adolescent Nutrition. 1(2). 98–107. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact